Last updated 2026-07-30
TL;DR
CJC-1295 raises GH and IGF-1 by mimicking GHRH; DAC versions extend that effect for days, no-DAC versions last hours. Human trial data on the DAC form comes mainly from a 2006 Journal of Clinical Endocrinology & Metabolism study. Real pros: sustained GH/IGF-1 elevation, once-weekly dosing option. Real cons: injection site reactions, unclear long-term safety, no FDA-approved product, and most "stacking" claims are unverified.
What is CJC-1295, in plain terms?
CJC-1295 is a synthetic peptide built to act like growth-hormone-releasing hormone (GHRH), the natural signal your hypothalamus sends to the pituitary to release growth hormone. It's a modified version of GHRH(1-29), the biologically active fragment of the full hormone, engineered to resist rapid breakdown in the blood [1]. There are two distinct versions sold under this name, and mixing them up is the single most common source of confusion online. One version carries a chemical tail called Drug Affinity Complex (DAC) that binds to albumin in the blood, stretching its half-life out to roughly 6 to 8 days in humans [1]. The other, often labeled "CJC-1295 without DAC" or sold under the name Mod GRF (1-29), has a half-life measured in minutes, not days [2]. That half-life difference isn't a minor technical footnote. It changes the entire dosing logic, which is why so many "CJC-1295 protocols" you'll find on forums contradict each other: half the posts are talking about a weekly-injection compound, the other half about something you'd need to inject multiple times a day. Neither version is FDA-approved for any use. Both are typically sold as "research chemicals," not medicines, and neither has a defined human dose approved by any regulatory body [3]. For a broader look at what people report from using it, see cjc-1295 reviews.
What are the real, evidence-backed benefits of CJC-1295?
The clearest documented benefit is sustained elevation of growth hormone and IGF-1 levels, and that comes from one primary human study: a 2006 trial published in the Journal of Clinical Endocrinology & Metabolism testing CJC-1295 with DAC in healthy adults. That study found that a single dose of CJC-1295 (with DAC) increased mean GH levels for 6 days and significantly elevated IGF-1 for up to 9 to 11 days, with the effect scaling by dose [1]. The study's own conclusion states that CJC-1295 "increased plasma GH and IGF-I levels in a dose-dependent manner" and that these increases were sustained "without any evidence of a change in safety parameters" over the study period [1]. That's a real, peer-reviewed finding, not forum lore, and it's the strongest data point anyone can point to for this compound. Multiple weekly doses in that same study produced mean IGF-1 increases of roughly 1.5 to 3 times baseline, sustained across the dosing period [1]. Beyond that single trial, the benefit case leans heavily on mechanism and on GHRH biology studied more broadly, plus a large body of user-reported experience that isn't controlled or verified. Reported benefits in that self-reported territory, better sleep, easier fat loss, faster recovery, are plausible given what elevated GH and IGF-1 do physiologically, but they haven't been measured against placebo in the population actually using it recreationally. If you want a sense of what people report month to month, cjc-1295 first month what to expect and cjc-1295 results timeline collect that experience without dressing it up as clinical proof.
What are the downsides and risks of CJC-1295?
The honest answer is that nobody has good long-term safety data on this, and that gap is itself the biggest con. The 2006 JCEM trial ran for a matter of weeks and monitored a small number of healthy adult subjects [1]. It did not track years of use, did not include people with existing metabolic conditions, and wasn't designed to catch rare adverse events. Anything claimed about long-term safety, cancer risk, cardiac effects, insulin resistance over years, is extrapolation, not established fact. Documented and plausible risks include: Injection site reactions: redness, swelling, or welts at the injection site are commonly reported with subcutaneous peptide injections generally [4]. Water retention and edema: growth hormone axis stimulation is known to cause fluid retention, a documented effect of GH-elevating compounds more broadly [5]. Blood sugar effects: GH antagonizes insulin action; sustained elevation could worsen insulin sensitivity in susceptible people, a mechanism well established for growth hormone itself [5]. Unknown purity and dosing: because these are sold outside the regulated pharmaceutical supply chain, there is no FDA oversight of manufacturing consistency, sterility, or labeled dose accuracy [3]. Legal and regulatory gray zone: CJC-1295 is not an FDA-approved drug and is not legal to sell for human consumption in the United States; it exists almost entirely under a "research use only" label that does not permit marketing for personal use [3]. That last point matters practically, more than legally. "Research use only" labeling means there's no batch-level accountability the way there is with a pharmacy-dispensed, provider-reviewed product, and quality varies a lot between sellers.
CJC-1295 with DAC vs without DAC: what's actually different?
| Half-life | ~6 to 8 days [1] | Minutes (roughly 5 to 30 min range reported in pharmacokinetic literature on GHRH analogs) [2] | |
|---|---|---|---|
| Typical injection frequency in studied/reported use | Weekly | Multiple times daily, often before meals/bedtime | |
| GH release pattern | Sustained, blunted pulsatility | Sharper, closer to a natural GH pulse | |
| Human trial data | Yes, JCEM 2006 dose-ranging study [1] | Limited; mostly mechanistic/animal and short pharmacokinetic work [2] | |
| Common pairing | Ipamorelin | Ipamorelin | The DAC version's whole appeal is convenience: less frequent injections, sustained IGF-1 elevation shown in an actual human trial. The tradeoff is that sustained, non-pulsatile GH elevation is a different physiological pattern than the body's natural pulsed release, and some researchers have raised the question of whether that matters for long-term pituitary sensitivity or side effect profile, though this hasn't been directly settled in humans [1]. The no-DAC version tries to mimic a more natural pulse by pairing frequent small doses with the body's own GH release rhythms, at the cost of needing several injections a day. Its human evidence base is thinner. Most of what circulates about no-DAC dosing schedules is bodybuilding-forum protocol, not published trial data. If someone tells you "CJC-1295" without specifying which version, ask. The two are not interchangeable in half-life, dosing frequency, or evidence base. |
This is the single most important distinction to get right before you read anything else about dosing or protocols. | Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |
Why is CJC-1295 usually paired with ipamorelin?
The rationale is mechanistic, not clinically proven as a combination. CJC-1295 is a GHRH analog, working on GHRH receptors in the pituitary. Ipamorelin is a ghrelin receptor agonist (a growth hormone secretagogue), working on an entirely separate receptor pathway [6]. Because they act on two different receptors that both converge on GH release, the theory is that combining them produces a larger GH pulse than either alone, similar to how GHRH and ghrelin work together naturally in the body's own regulation of GH secretion [6]. This dual-pathway logic is well established in endocrinology for GHRH and ghrelin generally. What's not established is a controlled human trial testing CJC-1295 plus ipamorelin against either compound alone, measuring outcomes people actually care about (body composition, strength, sleep quality) over a meaningful timeframe. The combined-effect argument is a reasonable extrapolation from separate mechanisms, not a demonstrated clinical outcome. Ipamorelin itself is attractive in this pairing because animal and early human data suggest it's more selective for GH release with less effect on cortisol and prolactin compared to older secretagogues like GHRP-6 [6], but selectivity in isolated studies doesn't automatically mean a superior combined result with CJC-1295 in practice. Anyone telling you the combination is "proven" to outperform either compound alone is overstating the evidence. It's a plausible, biologically grounded pairing. It is not a settled clinical outcome.
How much does CJC-1295 cost, and is the cost worth it?
Pricing varies widely by supplier, purity claims, and whether it's the DAC or no-DAC form, and there's no standardized retail price the way there is for an FDA-approved drug with an NDC code. Because this market is unregulated for human use, published price comparisons are inherently soft; treat any specific dollar figure you see online as anecdotal rather than authoritative. What you can evaluate is value relative to what the evidence supports: the JCEM trial data justifies expecting a measurable, dose-dependent IGF-1 rise from the DAC form over roughly 6 to 11 days per dose [1]. It doesn't justify expecting guaranteed fat loss, muscle gain, or anti-aging outcomes, those are extrapolations layered on top of a hormonal effect, not outcomes the trial itself measured. A useful cost framework: pay for consistent sourcing and provider review over the cheapest listing you can find. Because manufacturing isn't FDA-regulated for these peptides [3], the biggest financial risk isn't overpaying, it's paying for something underdosed, contaminated, or mislabeled. For a fuller cost-benefit breakdown, is cjc-1295 worth it walks through the tradeoffs in more depth.
What does a realistic timeline of effects look like?
Based on the pharmacokinetics in the JCEM trial, GH elevation from a single DAC dose peaks and tapers over about 6 days, while IGF-1 stays elevated longer, up to 9 to 11 days after a single administration [1]. With repeated weekly dosing, IGF-1 levels reportedly stabilize at an elevated plateau rather than spiking and crashing, based on the multi-dose data in that same study [1]. What this means practically: you would not expect visible body composition change in week one. The hormonal signal is measurable early, in blood tests, but visible or felt effects (if any) would lag behind that by weeks, following the general pattern of how IGF-1-mediated tissue changes accumulate over time in GH research broadly [5]. Most of what's written about week-by-week subjective experience, sleep changes, joint feel, appetite, is user-reported and not from controlled trials. Treat it as a pattern of anecdotes worth knowing about, not a guarantee. cjc-1295 results timeline and cjc-1295 before and after go through that self-reported timeline in more detail, clearly labeled as such.
How often does CJC-1295 actually work, and how do you judge "success"?
This is a harder question than it sounds, because there's no large-scale human trial measuring a defined "success rate" for CJC-1295 the way there is for an approved drug with an FDA-reviewed efficacy endpoint. The 2006 JCEM study measured hormonal biomarkers (GH, IGF-1) in a small group of healthy volunteers, not a success/failure rate against a functional outcome like strength gain or body fat percentage [1]. What we can say: the hormonal response (GH and IGF-1 rise) was consistent and dose-dependent across the study's subjects, meaning the mechanism reliably does what it's supposed to do at a biomarker level [1]. Whether that biomarker change reliably converts into the outcomes people actually want is the part without controlled evidence. Anyone quoting you a specific "success rate" percentage for subjective outcomes like muscle gain or fat loss is citing something that isn't in the peer-reviewed literature. For an honest treatment of this question, cjc-1295 success rate breaks down what can and can't be claimed.
Is CJC-1295 legal, and can a doctor prescribe it?
In the United States, CJC-1295 has no FDA approval for any human indication and is not a scheduled controlled substance under the Controlled Substances Act, which puts it in a regulatory gray zone rather than a clearly illegal or clearly legal category [3]. It's typically sold labeled "for research use only, not for human consumption," a label that legally restricts how it can be marketed even though enforcement against individual buyers is inconsistent. Because it isn't FDA-approved, a doctor cannot write a standard prescription for it the way they would for an approved drug. Some compounding pharmacies and telehealth clinics offer it through provider review processes tied to compounding regulations, but this differs meaningfully from FDA drug approval and the legal footing varies by state and by how the product is formulated and dispensed. If you're going to use it at all, sourcing through a pathway that includes provider review and a named, accountable pharmacy partner is a materially different risk profile than an anonymous online "research chemical" listing with no quality oversight. That's the core distinction CJC-1295 Co points people toward: a provider-reviewed route with a named fulfilling pharmacy, rather than an unaccountable gray-market listing.
What does the bodybuilding-forum lore get wrong?
A lot. The internet's dosing charts, stacking timelines, and "cycle" language for CJC-1295 mostly originate from user communities, not from the clinical literature, and some of it directly contradicts what's actually been measured. Common claims worth flagging: that CJC-1295 "burns fat directly" (the trial measured IGF-1 and GH, not fat mass) [1]; that specific injection timing relative to meals dramatically changes results (this is extrapolated from how endogenous GH pulses interact with insulin, not from a CJC-1295-specific trial); and that there's an established "best stack" combining three or four peptides (no controlled trial has tested these multi-peptide combinations against each other). None of this makes the compound useless or the community dishonest, people are working with real physiological logic and their own lived experience. But logic and anecdote aren't the same category of evidence as a peer-reviewed, dose-ranging human trial. When you're evaluating a claim, ask whether it traces back to the JCEM data, to broader GH/IGF-1 endocrinology, or purely to forum consensus. Those are three very different confidence levels, and conflating them is where most of the bad advice online comes from.
So, pros and cons: the honest summary
Pros, grounded in actual data: dose-dependent, measurable GH and IGF-1 elevation shown in a peer-reviewed human trial [1]; the DAC version offers a convenient weekly dosing interval rather than daily injections [1]; mechanistically sound pairing with ipamorelin based on well-established dual-pathway GH physiology [6]; sustained IGF-1 elevation over roughly a week per dose rather than a brief spike [1]. Cons, equally grounded: no FDA approval and no long-term human safety data beyond a short trial window [1][3]; unregulated manufacturing means sourcing quality varies enormously between sellers [3]; injection site reactions and fluid retention are plausible and reported side effects tied to the GH axis broadly [4][5]; most claims about fat loss, muscle gain, and multi-peptide stacking outperform mechanism aren't backed by controlled trials, they're extrapolation or forum lore; legal and regulatory status is a gray zone, not a clear green light. The net honest read: the biology is real and partially demonstrated in humans. The marketing built on top of that biology, in both directions (wonder compound or reckless danger), outpaces what the evidence actually says. If you're weighing whether it's worth it for your situation, is cjc-1295 worth it is the more decision-focused companion piece to this one.
Frequently asked questions
What is the main difference between CJC-1295 with DAC and without DAC?
DAC extends the half-life to roughly 6 to 8 days, allowing weekly dosing, while no-DAC CJC-1295 (Mod GRF 1-29) has a half-life of minutes and requires multiple daily injections to mimic a natural GH pulse. The DAC form has the stronger human trial data, from a 2006 JCEM study [1].
Is CJC-1295 FDA-approved?
No. CJC-1295 has no FDA approval for any human use and is typically sold labeled for research use only, not for human consumption. It is not a scheduled controlled substance, which places it in a regulatory gray zone rather than clearly legal or illegal for individual possession [3].
Does CJC-1295 actually increase growth hormone in humans?
Yes, in the one major controlled human trial available. A 2006 study in the Journal of Clinical Endocrinology & Metabolism found CJC-1295 (DAC) increased GH and IGF-1 in a dose-dependent way, with IGF-1 staying elevated for 9 to 11 days after a single dose [1].
Why do people combine CJC-1295 with ipamorelin?
CJC-1295 acts on GHRH receptors and ipamorelin acts on ghrelin receptors, a different pathway that also triggers GH release. Combining two distinct receptor pathways is a mechanistically sound idea based on established GH physiology, but no controlled trial has tested the combination against either compound alone for real-world outcomes [6].
What are the most common side effects of CJC-1295?
Reported issues include injection site redness or swelling, water retention, and potential effects on insulin sensitivity tied to sustained GH elevation. Long-term safety data doesn't exist beyond the short window of the 2006 trial, so rarer or delayed effects aren't well characterized [1][4][5].
How long does it take to see results from CJC-1295?
Hormonal changes (GH, IGF-1) are measurable within days based on trial pharmacokinetics, with IGF-1 staying elevated 9 to 11 days after a single DAC dose. Any visible or felt effects would lag well behind that biomarker change and aren't documented in controlled trials, only in user reports [1].
Is CJC-1295 the same as HGH?
No. HGH is the growth hormone itself, injected directly. CJC-1295 is a GHRH analog that signals your own pituitary to release more of your own GH, which is a different mechanism with a different risk and regulatory profile [1].
Can CJC-1295 help with fat loss?
There's no controlled trial measuring fat loss as an outcome for CJC-1295; the 2006 JCEM study measured GH and IGF-1 biomarkers, not body composition [1]. Fat loss claims are physiologically plausible given elevated GH's known metabolic effects, but they're extrapolation, not a demonstrated trial result.
Is CJC-1295 legal to buy and use in the United States?
It exists in a regulatory gray zone: not FDA-approved, not a scheduled controlled substance, typically sold as research use only. Enforcement against individual buyers is inconsistent, but that label legally restricts marketing for human consumption, and sourcing quality is not regulated the way approved drugs are [3].
How does CJC-1295 compare in cost to other GH secretagogues?
There's no standardized pricing because it's sold outside the FDA-regulated drug supply chain, so figures online vary widely by supplier and purity claims. The more useful comparison is sourcing accountability (provider review, named pharmacy partner) rather than chasing the lowest listed price.
What does the research say about long-term safety of CJC-1295?
Very little. The primary human trial ran for a short period and monitored a small group of healthy adults with no evidence of safety parameter changes during that window, but it wasn't designed to catch long-term or rare adverse effects [1]. Long-term safety claims in either direction go beyond what's been studied.
Does CJC-1295 without DAC work better than with DAC?
They're not directly comparable in the way that phrase implies. The DAC version has the human trial data and a weekly dosing schedule; the no-DAC version aims for a more natural pulsatile GH release pattern but has a thinner published evidence base, mostly pharmacokinetic and mechanistic work rather than outcome trials [1][2].
Sources
- Journal of Clinical Endocrinology & Metabolism, 2006 CJC-1295 dose-ranging study: CJC-1295 (with DAC) increased GH and IGF-1 in a dose-dependent manner, with IGF-1 elevated for 9-11 days after a single dose and no evidence of safety parameter changes
- National Center for Biotechnology Information, PubChem compound summary for CJC-1295: Structural and pharmacokinetic basis for the DAC vs non-DAC half-life distinction
- U.S. Food and Drug Administration, FDA-Approved Drug Products search guidance: CJC-1295 has no FDA-approved drug application and no regulated manufacturing oversight for human use
- MedlinePlus, Subcutaneous injection site reactions: Injection site redness, swelling, and welts are documented reactions to subcutaneous injections generally
- Endocrine Society, Growth Hormone and Metabolic Effects clinical resources: Growth hormone elevation is associated with fluid retention and effects on insulin sensitivity
- National Center for Biotechnology Information, PubChem compound summary for Ipamorelin: Ipamorelin acts as a selective ghrelin receptor agonist distinct from the GHRH pathway, providing the mechanistic basis for pairing with CJC-1295